<DOC>
	<DOCNO>NCT03005899</DOCNO>
	<brief_summary>This Phase 3 clinical trial compare safety efficacy SyB P-1501 SyB P-1501 placebo management first 24 hour post-operative pain .</brief_summary>
	<brief_title>Study SyB P-1501 ( Fentanyl HCI ) Treatment Postoperative Pain</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Patients meet inclusion criterion day inform consent one day surgery none exclusion criterion applicable eligible participate study . 1 . Expected require opioid analgesia management postoperative pain least 24 hour surgery require postoperative pain control 2 . Underwent one follow surgery general anesthesia : Abdominal surgery ( e.g. , gastrointestinal , gynecological ) Orthopedic surgery ( e.g. , spinal surgery ) Thoracic surgery ( e.g. , respiratory surgery require chest tube surgery ) 3 . ASA physical status I , II III 4 . Age : At least 20 year 5 . Sex : Men woman ( negative pregnancy test woman childbearing potential ) . 6 . Inpatient/outpatient status : Inpatient 7 . Received adequate information study give write consent participate study himself/herself 1 . Expected use continuous intraoperative postoperative analgesia local pain control technique ( e.g. , spinal/epidural analgesia , nerve block ) 2 . Scheduled body surface surgery ( e.g. , burn , breast reconstruction , skin graft ) 3 . Hypersensitive/allergic fentanyl , skin adhesive and/or cetylpyridinium chloride 4 . Expected/scheduled undergo additional surgical procedure within 36 hour postoperation 5 . Known suspected opioid tolerance 6 . Skin disorder precludes application investigational product 7 . Increased intracranial pressure 8 . Concomitant asthma , severe respiratory disorder 9 . Having convulsive seizure attack within 5 year 10 . Patient medical device implant body , cardiac pacemaker implantable defibrillator 11 . History opioid , drug and/or alcohol abuse 12 . Women pregnant , might pregnant , breastfeed 13 . Using investigational drug , use investigational drug within last 6 month 14 . Otherwise determine ineligible participate study discretion principal investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>